about
Phase II study of weekly oxaliplatin and 24-h infusion of high-dose 5-fluorouracil and folinic acid in the treatment of advanced gastric cancer.Salvage chemotherapy with mitomycin, docetaxel, and irinotecan (MDI regimen) in metastatic pancreatic adenocarcinoma: a phase I and II trial.Salvage chemotherapy with irinotecan, 5-fluorouracil and leucovorin for taxane- and cisplatin-refractory, metastatic gastric cancerA multicenter, phase I, dose-escalation study to assess the safety, tolerability, and pharmacokinetics of etirinotecan pegol in patients with refractory solid tumorsIrinotecan and oxaliplatin: an overview of the novel chemotherapeutic options for the treatment of advanced colorectal cancer.Functional-segregated coumarin-containing telodendrimer nanocarriers for efficient delivery of SN-38 for colon cancer treatment.Camptothecin and its analogues: a review on their chemotherapeutic potential.Downregulation of Sp1 by Minnelide leads to decrease in HSP70 and decrease in tumor burden of gastric cancerIrinotecan, docetaxel and oxaliplatin combination in metastatic gastric or gastroesophageal junction adenocarcinoma.Significance of Kampo, traditional Japanese medicine, in supportive care of cancer patientsA pilot study of cisplatin, irinotecan, leucovorin and 5-fluorouracil (PILF) combination chemotherapy for advanced gastric cancer.Polypeptide-based Micelles for Delivery of Irinotecan: Physicochemical and In vivo Characterization.Phase II study of docetaxel in patients with pancreatic cancer previously untreated with cytotoxic chemotherapy.Successful treatment of small-cell lung cancer with irinotecan in a hemodialysis patient with end-stage renal disease.Retrospective comparison of single-agent chemotherapy with weekly 5-fluorouracil or weekly irinotecan in previously treated patients with metastatic colorectal cancer.Phase II trial of irinotecan in combination with amifostine in patients with advanced colorectal carcinoma.Dimeric camptothecin-loaded RGD-modified targeted cationic polypeptide-based micelles with high drug loading capacity and redox-responsive drug release capability.Functionalized Nanoparticles Efficiently Enhancing the Targeted Delivery, Tumor Penetration, and Anticancer Activity of 7-Ethyl-10-Hydroxycamptothecin.Berberine hydrochloride counteracts enhanced IL-8 expression induced by SN 38 in AGS cells.
P2860
Q33361500-A63B4020-5242-4623-932B-9DE6C31F0685Q33364008-E38F4C66-CEA6-40E7-BA01-D5A068A10DDBQ33366124-8E5BF714-35F8-43FA-8C7D-59F0E251A678Q33924277-A6D8ED30-08BD-4FB0-A717-3558EB46A241Q34342186-78C165A1-6C6C-4DB0-95CE-F575748AB0EBQ35655672-03490087-48F5-4981-BA7F-1D4C5A7E3225Q36153120-7454623D-BAF3-4FAE-970F-747C9A25BBD5Q36278712-CEDD5E4D-B2D9-4EA8-999F-62E927E69FE4Q36611088-8ECF14FE-117A-4C26-AF94-1744CC34962EQ36990461-609CACBD-9CF5-4C2A-8E9C-438DB11D5B77Q37341735-1AA8F944-4ADF-41DA-A252-D67CDCD1C889Q38932548-0E7DADEF-5C2A-4E7C-B54B-3797CF23349FQ40579509-149D06AB-7F5A-44DC-A44E-83FFDD988333Q41778610-F39449EA-38C5-4326-8A57-C1562B1300F9Q43916928-7D5AAC0F-46D1-4DC8-8D4B-9F6E2027BFD1Q43986810-F15B12E5-9E2D-47A9-8BB5-BB31129692DFQ47804930-216303A4-8F06-4469-A65D-004682AF87E7Q48243945-35627AB4-EC3A-493E-BCF7-901EF7535936Q50906698-3DAE3172-3304-404B-8F29-EBA3FD03601E
P2860
description
1999 nî lūn-bûn
@nan
1999 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի մարտին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
CPT-11 in gastrointestinal cancer.
@ast
CPT-11 in gastrointestinal cancer.
@en
type
label
CPT-11 in gastrointestinal cancer.
@ast
CPT-11 in gastrointestinal cancer.
@en
prefLabel
CPT-11 in gastrointestinal cancer.
@ast
CPT-11 in gastrointestinal cancer.
@en
P1476
CPT-11 in gastrointestinal cancer.
@en
P2093
H Bleiberg
P304
P356
10.1016/S0959-8049(98)00423-7
P577
1999-03-01T00:00:00Z